Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients

摘要

IntroductionProtease inhibitors might be sufficient to maintain complete virological suppression when used as monotherapy for HIV-1-positive patients who have achieved sustained virological suppression on combination antiretroviral therapy (ART). The present study estimated the cost-effectiveness of a strategy of switching the ART to protease inhibitor monotherapy (PIM) with prompt return to combination therapy in the event of viral load rebound compared to continuing the ongoing triple-therapy (OTT) in the long-term management of HIV-1-positive patients.